Precision BioSciences to Report Fourth Quarter and Fiscal Year 2020 Financial Results on March 18, 2021GlobeNewsWire • 03/12/21
Will Precision BioSciences (DTIL) Report Negative Q4 Earnings? What You Should KnowZacks Investment Research • 03/02/21
Precision Bio's ARCUS Gene Editing Platform Is Safe, Durable; Long-Term Animal Study ShowsBenzinga • 02/19/21
Precision Announces 3-Year Pre-clinical Study Results Showing Long-term Durability and Safety of ARCUS In Vivo Gene Editing to Cut LDL Cholesterol Levels in Nonhuman PrimatesGlobeNewsWire • 02/19/21
Precision BioSciences Announces FDA Accepts IND for PBCAR19B, a Next-Generation, Stealth Cell, CD19 Allogeneic CAR T Candidate for Non-Hodgkin LymphomaGlobeNewsWire • 01/19/21
Precision BioSciences Announces Closing of In Vivo Gene Editing Collaboration and License Agreement with Eli Lilly and CompanyGlobeNewsWire • 01/07/21
Precision BioSciences Reports Positive Interim Results from PBCAR0191 Phase 1/2a Trial in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and R/R B-cell Acute Lymphoblastic Leukemia (B-ALL)GlobeNewsWire • 12/04/20
Precision BioSciences to Present at the Piper Sandler 32nd Annual Virtual Healthcare ConferenceGlobeNewsWire • 11/24/20
Lilly and Precision BioSciences Announce Genome Editing Research Collaboration and License AgreementPRNewsWire • 11/20/20
Precision BioSciences Reports Third Quarter 2020 Financial Results and Provides Business UpdateGlobeNewsWire • 11/10/20
Earnings Preview: Precision BioSciences (DTIL) Q3 Earnings Expected to DeclineZacks Investment Research • 11/03/20
Precision BioSciences to Report Third Quarter 2020 Financial Results on November 10, 2020GlobeNewsWire • 11/03/20
Precision Bio: 2020 Is Not Looking Great With 2 Terminated Partnerships And Cash Down -30% To $127M.Seeking Alpha • 10/26/20
Precision BioSciences Announces U.S. Patent Trial and Appeal Board Upholds Allogeneic CAR T PatentsGlobeNewsWire • 10/15/20
Precision BioSciences to Present at Upcoming Virtual Investor Conferences in OctoberGlobeNewsWire • 09/28/20
Precision BioSciences and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate PBCAR269A in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple MyelomaGlobeNewsWire • 09/21/20
Precision BioSciences Receives Fast Track Designation from U.S. Food and Drug Administration for PBCAR269A, an Investigational Allogeneic CAR T Therapy for Relapsed/Refractory Multiple MyelomaGlobeNewsWire • 09/09/20